IQVIA Holdings Price to Free Cash Flow Ratio 2011-2024 | IQV

IQVIA Holdings current price to free cash flow ratio as of November 25, 2024 is 18.82.

  • IQVIA Holdings average price to free cash flow ratio for 2023 was 27.16, a 16.42% decline from 2022.
  • IQVIA Holdings average price to free cash flow ratio for 2022 was 23.33, a 10.2% increase from 2021.
  • IQVIA Holdings average price to free cash flow ratio for 2021 was 21.17, a 18.8% increase from 2020.

Price to free cash flow ratio can be defined as

IQVIA Holdings Price to Free Cash Flow Ratio 2011-2024 | IQV

  • IQVIA Holdings average price to free cash flow ratio for 2023 was 27.16, a 16.42% decline from 2022.
  • IQVIA Holdings average price to free cash flow ratio for 2022 was 23.33, a 10.2% increase from 2021.
  • IQVIA Holdings average price to free cash flow ratio for 2021 was 21.17, a 18.8% increase from 2020.

Price to free cash flow ratio can be defined as

Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$196.3B
Intuitive Surgical (ISRG)$195.1B
Alcon (ALC)$42.4B
Edwards Lifesciences (EW)$41.6B
IDEXX Laboratories (IDXX)$34.2B
DexCom (DXCM)$28.4B
Waters (WAT)$22.2B
STERIS (STE)$21.2B
SONOVA HOLDING (SONVY)$20.8B
Hologic (HOLX)$18.3B
Fresenius Medical Care AG KGaA (FMS)$13B
Sysmex ADR (SSMXY)$12.9B
Globus Medical (GMED)$11.5B
Penumbra (PEN)$9.4B
Masimo (MASI)$9.3B
Teleflex (TFX)$8.9B
Glaukos (GKOS)$7.9B
PROCEPT BioRobotics (PRCT)$4.9B
Integer Holdings (ITGR)$4.6B
Veracyte (VCYT)$3.1B
Inari Medical (NARI)$2.9B
LivaNova (LIVN)$2.8B
TransMedics (TMDX)$2.6B
Nihon Kohden (NHNKY)$2.5B
Elekta AB (EKTAY)$2.2B
Tandem Diabetes Care (TNDM)$2B
Integra LifeSciences Holdings (IART)$1.8B
RxSight (RXST)$1.8B
Alphatec Holdings (ATEC)$1.4B
Artivion (AORT)$1.2B